Anticonvulsant and antiepileptic actions of 2‐deoxy‐D‐glucose in epilepsy models

Abstract

The glycolytic inhibitor 2DG exerts acute anticonvulsant and chronic antiepileptic actions, and has a novel pattern of effectiveness in preclinical screening models. These results identify metabolic regulation as a potential therapeutic target for seizure suppression and modification of epileptogenesis.